PETALING JAYA: Fertility care specialist Alpha IVF Group Bhd has set its sights on Jakarta for the group’s second in-vitro fertilisation (IVF) centre in Indonesia, following the signing of a clinical space lease through its subsidiary, PT Alpha IVF Dan SPOG Jakarta, with PT Surya Inter Wiesa to secure a location for the facility.
The new centre will be located within Banten’s Special Economic Zone (SEZ) at the Biomedical Campus in Bumi Serpong Damai City, part of the Greater Jakarta metropolitan region, or Jabodetabek.
The facility will benefit from a supportive regulatory environment and operating incentives in the SEZ aimed at attracting advanced healthcare investments. It will enjoy tax incentives, streamlined regulatory processes, access to specialised pharmaceutical supply chains and the ability to engage foreign medical specialists.
The Banten SEZ is designated for international health, technology and education and is privately managed by Sinar Mas Land.
The centre is targeted to commence operations in October.
The expansion marks Alpha IVF Group’s second IVF development in Indonesia, following its Bali IVF centre, currently under construction in the Sanur Special Economic Zone, which is expected to begin operations in 2027.
Indonesia represents one of the largest untapped fertility treatment markets in Asia.
Despite a population exceeding 270 million, IVF penetration remains relatively low compared with more mature healthcare markets, highlighting significant long-term growth potential for assisted reproductive services.
Within Indonesia, demand for fertility treatment is concentrated in Jabodetabek.
In 2024, a total of 15,041 assisted reproductive technology cycles were performed nationwide, of which 6,342 cycles, representing more than 42% of the national total, were performed in Jabodetabek, according to the Perfitri Report 2024.
Alpha IVF Group group managing director Datuk Dr Colin Lee Soon Soo said the Greater Jakarta metropolitan area, with a population of about 35 million, is one of Southeast Asia’s largest potential fertility markets.
“Based on global IVF benchmarks, the region would need around 45,000 IVF cycles annually, yet only 6,342 cycles were performed in 2024, highlighting significant unmet demand.
“With fertility procedures heavily concentrated in the Jabodetabek region, Jakarta is a strategically important market for Alpha IVF Group.
“Locating our centre within this ecosystem allows us to directly access the country’s largest fertility patient base while leveraging the operational advantages of the SEZ.
“Together with our upcoming Bali centre, the expansion strengthens our regional platform and positions Alpha IVF Group to capture long-term growth opportunities in Indonesia,” he said.
Alpha IVF Group has secured about 612.46 square metres of clinical and laboratory space for the centre.
The group aims to incur total capital expenditure of 47 billion rupiah (RM10.9 million), to be funded through proceeds from an initial public offering and internally generated funds.
The centre will feature the group’s proprietary technologies and laboratory optimisation systems, including Cryotec vitrification, time-lapse embryoscope, preimplantation genetic testing and utilising advanced artificial intelligence to enhance embryo selection.
Senior IVF specialists from Malaysia and Singapore will work alongside Indonesian fertility specialists to make internationally benchmarked standards of IVF success rates available locally.
The centre in Jakarta is expected to commence operations ahead of the group’s Bali IVF centre, accelerating Alpha IVF Group’s presence in Indonesia’s largest fertility treatment market and strengthening earnings visibility from the region.